$0.50
−5.13%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.53
From 52W high−65.80%
Volume2.07M
Market cap$16.80M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$0.53
From 52W high
−65.80%
Volume
2.07M
Market cap
$16.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.2x
P/E (TTM)
—
RSI (14)
57.8
MomentumView details →
1D Return
−5.13%
YTD Return
−61.64%
SummaryUpdated Jun 1, 2026
Pasithea Therapeutics Corp. (NASDAQ:KTTA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Miami Beach, Florida. The company went public in September 2021 and focuses on developing treatments for psychiatric and neurological disorders. Pasithea operates as a pre-revenue biotech company conducting research and discovery activities while also planning to establish anti-depression treatment clinics that would offer ketamine infusion therapies administered by trained pharmacists.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration cleared Pasithea Therapeutics’ IND application for a randomized, placebo-controlled Phase 2 trial of PAS-004 in patients with NF1-associated cutaneous neurofibromas.1d agoPasithea Therapeutics Corp. reported clinical data showing prolonged stable disease in patients receiving PAS-004 in a Phase 1 advanced cancer study, with four patients treated for more than 300 days and two for more than 500 days; the company also described the drug’s safety profile as favorable.12d agoThe FDA granted Orphan Drug Designation to Pasithea Therapeutics' PAS-004 for the treatment of ALS.155d ago